Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program
Year: 2024
Type: article
Study design: Observational Study
Abstract: Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access programNovel immunotherapeutic approaches are revolutionizing the treatment of triple-class exposed patients with relapsed and refractory multiple myeloma (RRMM). 1 Teclistamab is the first bispecific antibody targeting BCMA and CD3 to be approved for the treatment of RRMM.The pivotal study for this approval was MajesTEC-1, a phase I/II, single-arm, open-label, multicenter, multicohort study. 2 Eligible patients had RRMM after at least three lines of therapy, including exposure to a proteasome inhibitor (PI), an immunomodula-tory drug (IMiD), and an anti-CD38 antibody, with an Eastern Cooperative Oncology Group Performance Status score of 0 or 1. Prior treatment with a BCMA-targeted therapy was not permitted.Among 165 patients (median, 5 prior lines of therapy), 78% were refractory to all three classes, and the overall response rate (ORR) (primary endpoint) was 63.0%, with 65 patients (39.4%) achieving a complete response (CR) or better.Response rates were lower in patients with extramedullary disease (EMD), stage 3 disease, and more
Source: Haematologica
Authors: Aurore Perrot, Cyrille Hulin, Ariane Boumendil, Hamza Manjra, Antoine Leveque, Carolyne Croizier, Arthur Dony, Mohamad Mohty, Murielle Roussel, Salomon Manier, Frédérique Orsini-Piocelle, Loic Bauschert, Arthur Bobin, Laurent Frenzel, Laure Vincent, Claire Breal, Jean Richard Eveillard, Thomas Gerome, Mourad Tiab, Emilie Chalayer, Rakiba Belkhir, Clara Mariette, Perrine Moyer, Thomas Chalopin, Brieuc Cherel, Lydia Montes, Arthur Coste, Reza Tabrizi, Lionel Karlin, Daniella Robu, Amandine Huguet, Stéphanie Harel, Philippe Moreau
Institutions: Centre Hospitalier Universitaire de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Institut universitaire du cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Bordeaux, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Intergroupe Francophone du Myélome, Institut Paoli-Calmettes, Institut de Cancérologie Strasbourg, Centre Hospitalier Universitaire de Clermont-Ferrand, Institut d’Hématologie et d’Oncologie Pédiatrique, Hospices Civils de Lyon, Centre Hospitalier Métropole Savoie, Laboratoire d'hématologie, Centre Hospitalier Universitaire de Limoges, Contrôle de la Réponse Immune B et Lymphoproliférations, Université de Limoges, Centre Hospitalier Universitaire de Lille, Centre Hospitalier Annecy Genevois, Centre Hospitalier Universitaire de Poitiers, Hôpital Necker-Enfants Malades, Institut des Maladies Génétiques Imagine, Centre Hospitalier Universitaire de Montpellier, Hôpital Cochin, Centre Hospitalier de Bretagne Sud, Centre Hospitalier Régional Universitaire de Brest, Centre Hospitalier Universitaire de Caen Normandie, Université de Caen Normandie, Centre Hospitalier Départemental Vendée, Centre Hospitalier Universitaire de Saint-Étienne, Bicêtre Hospital, Centre Hospitalier Universitaire de Grenoble, Centre Hospitalier Universitaire de Nantes, Nantes Université, Centre Hospitalier Universitaire de Tours, Centre hospitalier Bretagne Atlantique, Centre Hospitalier Universitaire Amiens-Picardie, Centre Hospitalier Universitaire de Reims, Hôpital Lyon Sud, Centre International de Recherche en Infectiologie, Centre Hospitalier de Lens, Hôpital Saint-Louis
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W4404585817